rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

OraSure Technologies, Inc.

OSUR · Nasdaq

Health CareMedical DevicesJust started moving

OSUR stood above a rising 150-day average in 22 of the last 52 weekly readings, including each of the last 5 weeks. It is 0.5% above that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−7 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Just started moving
Weeks in an uptrend
5 in a row
Industry in uptrend
27% -7 in 4 wk
Insider buys, 12 months
$1.1M
Insider sales, 12 months
$0
Officials’ trades on record
5
Institutions holding
174 (+12)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 22 of 52 weeks.

20 Apr – 19 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$734KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

5 disclosed lines: House 5, Senate 0, executive 0; 1 people.

WhoDidAmountTraded
Tom Malinowski House: U.S. House ClerkNJ07sold$15k–$50k23 Feb 2021filed 6 Mar 2021
Tom Malinowski House: U.S. House ClerkNJ07sold$1k–$15k11 Jan 2021filed 5 Mar 2021
Tom Malinowski House: U.S. House ClerkNJ07sold$15k–$50k9 Dec 2020filed 5 Mar 2021
Tom Malinowski House: U.S. House ClerkNJ07sold$1k–$15k8 Oct 2020filed 26 Aug 2021
Tom Malinowski House: U.S. House ClerkNJ07sold$15k–$50k7 Oct 2020filed 5 Mar 2021

Insiders

Buy orders, 12 months8
Sale orders, 12 months0
Buyers · sellers4 · 0
WhoDidSharesTraded
Steven Kyle BoydDirectorbought25,000at $2.9914 May 2026filed 14 May 2026
Steven Kyle BoydDirectorbought25,000at $3.0213 May 2026filed 14 May 2026
Steven Kyle BoydDirectorbought25,000at $2.9812 May 2026filed 14 May 2026
Manner Carrie EglintonPresident & CEObought32,300at $2.9320 Mar 2026filed 23 Mar 2026
Kenneth J. McGrathChief Financial Officerbought32,300at $2.9320 Mar 2026filed 23 Mar 2026
Manner Carrie EglintonPresident & CEObought22,022at $3.0013 Mar 2026filed 16 Mar 2026
Kenneth J. McGrathChief Financial Officerbought22,021at $3.0013 Mar 2026filed 16 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders174+12 on the quarter
New · exited31 · 21
Reported value$274.3M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 202612,250,230$35.7M+352,688+3.0%
SAPPHIRE VENTURES, L.P.unchanged · filed 14 Aug 20267,980,295$10.4M00.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20266,777,730$18.4M+6,863+0.1%
GAGNON SECURITIES LLCreduced · filed 5 Aug 20264,859,146$11.3M-134,181−2.7%
NEUBERGER BERMAN GROUP LLCadded · filed 13 Aug 20264,685,432$20.9M+323,531+7.4%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20264,102,264$11.0M+38,885+1.0%
PRIVATE MANAGEMENT GROUP INCreduced · filed 31 Jul 20263,797,682$16.9M-1,624,447−30.0%
STATE STREET CORPreduced · filed 7 Aug 20263,299,630$9.6M-17,037−0.5%
SYSTEMATIC FINANCIAL MANAGEMENT LPadded · filed 14 Aug 20262,857,974$12.7M+377,491+15.2%
RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 20262,722,103$9.9M-15,500−0.6%
31 Mar 2023 – 30 Jun 2026
162185208Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Steven Kyle Boyd Company insiderDirector · last 29 Sep 20263 · 0
John P. Kenny Company insiderDirector · last 6 Sep 20261 · 0
John D. Bertrand Company insiderDirector · last 3 Jun 20260 · 0
Lelio Marmora Company insiderDirector · last 3 Jun 20261 · 0
Nancy J. Gagliano Company insiderDirector · last 3 Jun 20263 · 0
Robert W. McMahon Company insiderDirector · last 3 Jun 20260 · 0
Kenneth J. McGrath Company insiderChief Financial Officer · last 20 Mar 20264 · 0
Manner Carrie Eglinton Company insiderPresident & CEO · last 20 Mar 20264 · 0
Michele Marie Anthony Company insiderSVP Finance & CAO · last 2 Mar 20260 · 1
David Shulkin Company insiderDirector · last 14 May 20250 · 0
Mara G. Aspinall Company insiderDirector · last 14 May 20252 · 0
Kathleen Gallagher Weber Company insiderChief Product Officer · last 1 Mar 20250 · 2

Same industry

RCEL Avita MedicalLeading+100%
HAE HaemoneticsLeading+48%
ATRC AtriCureLeading+47%
HTFL HeartflowLeading+47%

Distance from each stock’s own 150-day average.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202541.9%
Operating profit marginFY 2025 · to 31 Dec 2025-62.6%
Free cash flow marginFY 2025 · to 31 Dec 2025-46.3%
Return on capital employedFY 2025 · to 31 Dec 2025-19.8%
Research spendFY 2025 · to 31 Dec 202537.0%
Share count trendFY 2025 · to 28 Feb 2026-1.8%
Cash and equivalentsFY 2025 · to 31 Dec 2025$199.3M
Free cash flowFY 2025 · to 31 Dec 2025−$53.2M

Analyst forecasts

No analyst forecasts yet.